EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association of perioperative use of statins, metformin, and aspirin with recurrence after curative liver resection in patients with hepatocellular carcinoma: A propensity score matching analysis

Elias Khajeh iD, Ehsan Aminizadeh, Arash Dooghaie Moghadam, Ali Ramouz, Rosa Klotz, Mohammad Golriz, Uta Merle, Christoph Springfeld, De-Hua Chang, Thomas Longerich, Markus W Büchler, Arianeb Mehrabi iD

Cancer Medicine · 2023

DOI: 10.1002/cam4.6569 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Elias Khajeh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Metformin, Liver Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Statins, metformin, and aspirin have been reported to reduce the incidence of hepatocellular carcinoma (HCC). However, the effect of their perioperative use on survival outcomes of HCC patients following curative liver resection still remains unclear.

Method

Three hundred and fifty three patients with a first diagnosis of HCC who underwent curative liver resection were included. Propensity score matching analysis with a users: nonusers ratio of 1:2 were performed for each of the medications (statins, metformin, and aspirin). Overall survival (OS) and recurrence‐free survival (RFS) were evaluated and multivariable Cox proportional hazard analysis was performed.

Results

Sixty two patients received statins, 48 patients used metformin, and 53 patients received aspirin for ≥90 days before surgery. None of the medications improved OS. RFS of statin users was significantly longer than that of nonusers ( p = 0.021) in the matched cohort. Users of hydrophilic statins, but not lipophilic ones had a significantly longer RFS than nonusers. Multivariable analysis showed that statin use significantly improved RFS (hazard ratio [HR]: 0.41, 95% confidence interval [CI]: 0.17–0.97, p = 0.044). No difference was seen in RFS between metformin users and nonusers. Among patients with diabetes, RFS was nonsignificantly longer in metformin users than in non‐metformin users (84.1% vs. 60.85%, p = 0.069) in the matched cohort. No difference in postoperative RFS was seen between aspirin users and nonusers.

Conclusion

Preoperative use of statins in patients with HCC can increase RFS after curative liver resection, but metformin and aspirin were not associated with improved survival. Randomized controlled trials are needed to confirm the findings of the present study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularHydroxymethylglutaryl-CoA Reductase InhibitorsMetforminLiver NeoplasmsHumansPropensity ScoreAspirinRetrospective StudiesHepatectomy

Stichwörter der Autor:innen

aspirinhepatocellular carcinomaliver resectionmetforminstatinsurvival

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsMetforminAspirin

Autor:innen und Institutionen

  • Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
  • Liver Cancer Center Heidelberg (LCCH), Heidelberg University Hospital, Heidelberg, Germany.
  • Department of Internal Medicine IV, Gastroenterology & Hepatology, Heidelberg University Hospital, Heidelberg, Germany.
  • Department of Medical Oncology, National Center for Tumor Diseases Heidelberg University Hospital, Heidelberg, Germany.
  • Department of Diagnostic and Interventional Radiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.

ORCID-Profile: Elias Khajeh, Arianeb Mehrabi

Zitieren

APA

Khajeh, E., Aminizadeh, E., Moghadam, A. D., Ramouz, A., Klotz, R., Golriz, M., Merle, U., Springfeld, C., Chang, D. H., Longerich, T., Büchler, M. W., & Mehrabi, A. (2023). Association of perioperative use of statins, metformin, and aspirin with recurrence after curative liver resection in patients with hepatocellular carcinoma: A propensity score matching analysis. Cancer Medicine. https://doi.org/10.1002/cam4.6569

Vancouver

Khajeh E, Aminizadeh E, Moghadam AD, Ramouz A, Klotz R, Golriz M, et al. Association of perioperative use of statins, metformin, and aspirin with recurrence after curative liver resection in patients with hepatocellular carcinoma: A propensity score matching analysis. Cancer Medicine. 2023. doi:10.1002/cam4.6569

BibTeX
@article{Khajeh2023,
  author = {Khajeh, Elias and Aminizadeh, Ehsan and Moghadam, Arash Dooghaie and Ramouz, Ali and Klotz, Rosa and Golriz, Mohammad and Merle, Uta and Springfeld, Christoph and Chang, De-Hua and Longerich, Thomas and Büchler, Markus W and Mehrabi, Arianeb},
  title = {Association of perioperative use of statins, metformin, and aspirin with recurrence after curative liver resection in patients with hepatocellular carcinoma: A propensity score matching analysis},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6569}
}
Kostenlos starten →